Literature DB >> 2328751

Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers.

W Krause1, G Kühne, N Sauerbrey.   

Abstract

Plasma levels of S-(+)-rolipram and R-(-)-rolipram in six healthy male volunteers were measured by radioimmunoassay after intravenous injection of 0.1 mg and oral administration of 1.0 mg of the pure enantiomers. Following i.v. treatment, plasma levels of both isomers declined in three phases, with half-lives of 0.2 h, 0.6-0.9 h and 6-8 h. Total clearance was 6 ml.min-1.kg-1. Oral administration of 1.0 mg gave a peak concentration of 16 ng.ml-1 after 0.5 h. Bioavailability of (+)-rolipram was 77% and of the (-) enantiomer it was 74%. There was no significant difference in Cmax, half-life, total clearance or bioavailability between the two enantiomers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328751     DOI: 10.1007/bf00314807

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview.

Authors:  D E Drayer
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875

Review 2.  On chiral drug action.

Authors:  M Simonyi
Journal:  Med Res Rev       Date:  1984 Jul-Sep       Impact factor: 12.944

Review 3.  [False stereochemical tracks in pharmacotherapy].

Authors:  E J Ariëns; K Mohr
Journal:  Dtsch Med Wochenschr       Date:  1985-11-08       Impact factor: 0.628

4.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Pharmacokinetics of the antidepressant rolipram in healthy volunteers.

Authors:  W Krause; G Kühne; H Matthes
Journal:  Xenobiotica       Date:  1989-06       Impact factor: 1.908

6.  Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.

Authors:  M Eichelbaum; G Mikus; B Vogelgesang
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

7.  Stereoselective clearance and distribution of intravenous propranolol.

Authors:  L S Olanoff; T Walle; U K Walle; T D Cowart; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

8.  Stereoselective ring oxidation of propranolol in man.

Authors:  T Walle; U K Walle; M J Wilson; T C Fagan; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

9.  The influence of rolipram on the central serotoninergic system.

Authors:  E Przegalínski; K Bigajska; A Lewandowska
Journal:  Pharmacopsychiatria       Date:  1981-09

10.  Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences.

Authors:  W Krause; G Kühne
Journal:  Xenobiotica       Date:  1988-05       Impact factor: 1.908

View more
  3 in total

1.  Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.

Authors:  J E Souness; L C Scott
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

2.  Lipidic nanocapsule drug delivery: neuronal protection for cochlear implant optimization.

Authors:  Hartwig Meyer; Timo Stöver; Florian Fouchet; Guillaume Bastiat; Patrick Saulnier; Wolfgang Bäumer; Thomas Lenarz; Verena Scheper
Journal:  Int J Nanomedicine       Date:  2012-05-15

3.  Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior.

Authors:  Graeme B Bolger; Lisa High Mitchell Smoot; Thomas van Groen
Journal:  Int J Mol Sci       Date:  2020-08-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.